Anti-Hypertensive Medication in Geriatric Population with HFpEF

Abstract

INTRODUCTION Heart failure with preserved ejection fraction (HFpEF) is a condition where the left ventricular function is ≥50%. This population has a high morbidity and mortality compared to its counter-part heart failure with reduced ejection fraction (HFrEF). However treatment in this group remain spares. Hypertension medications are widely used in practice for patients with heart failure with reduced ejection fraction, however its efficacy in HFpEF is still an ongoing research. METHOD Evidence based research from various different search engines such as Medline® , Cochrane ® , and Proquest® with inclusion of high quality evidence such as meta-analysis, systematic review, RCT, and cohort studies. The selected papers were screened for validity, importance and applicability to the case in question. RESULT The two different RCTs studies showed that ACE-I had no effects in HFpEF. Research by Kitzman et al. showed that ACE-I did not show any improvement of left ventricular mass, neuro-hormonal profile, and 6 minutes walking test. This was also confirmed by Zi et al., which in addition showed that ACE-I did not increase the quality of life in the geriatric subjects. CONCLUSION All in all, ACE-I as a type of anti-hypertensive medication does not benefit geriatric population of HFpEF